Ernexa Therapeutics, Inc. (ERNA)
1.88
+0.05
(+2.73%)
USD |
NASDAQ |
Nov 06, 16:00
1.85
-0.03
(-1.60%)
After-Hours: 20:00
Ernexa Therapeutics Research and Development Expense (Quarterly) : 1.871M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.871M |
| June 30, 2026 | 2.792M |
| March 31, 2026 | 1.915M |
| December 31, 2025 | 0.676M |
| September 30, 2025 | 1.035M |
| June 30, 2025 | 1.136M |
| March 31, 2025 | 1.309M |
| December 31, 2024 | 1.158M |
| September 30, 2024 | 1.001M |
| June 30, 2024 | 0.987M |
| March 31, 2024 | 1.458M |
| December 31, 2023 | 1.21M |
| September 30, 2023 | 1.457M |
| June 30, 2023 | 1.579M |
| March 31, 2023 | 1.674M |
| December 31, 2022 | 1.962M |
| September 30, 2022 | 4.963M |
| June 30, 2022 | 1.685M |
| March 31, 2022 | 1.282M |
| December 31, 2021 | 4.249M |
| September 30, 2021 | 1.491M |
| June 30, 2021 | 5.432M |
| March 31, 2021 | 1.533M |
| December 31, 2020 | 1.651M |
| September 30, 2020 | 0.9235M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.9851M |
| March 31, 2020 | -0.039M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.00 |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cerenome, Inc. | 4.265M |
| ACADIA Pharmaceuticals, Inc. | 76.28M |
| Alnylam Pharmaceuticals, Inc. | 408.54M |
| Anika Therapeutics, Inc. | 7.895M |
| Savara, Inc. | 21.95M |